Despite a large number of studies on biomarkers for glioblastoma, only one has regularly been applied for prognostic stratification in routine clinical use: Promoter methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene in tumor tissue. This evidence concerns the gene MGMT and neoplasm.